NEW YORK (Reuters Health) – A European study indicates that patients with T-cell prolymphocytic leukemia may respond well to induction chemotherapy using fludarabine, mitoxantrone and cyclophosphamide, followed by…
By David Douglas NEW YORK (Reuters Health) – Surgical resection of isolated pulmonary metastases can prolong overall survival in breast cancer patients, German researchers say. “On the basis…
NEW YORK (Reuters Health) – For women with HER2-positive breast cancer, trastuzumab is as beneficial in those with invasive lobular disease as those with invasive ductal carcinoma, according…
NEW YORK (Reuters Health) – A European study indicates that patients with T-cell prolymphocytic leukemia may respond well to induction chemotherapy using fludarabine, mitoxantrone and cyclophosphamide, followed by…
NEW YORK (Reuters Health) – Environmental factors appear to influence the incidence of papillary thyroid microcarcinomas (PTMCs), according to a comparison of epidemiologic data from Sicily and the…
NEW YORK (Reuters Health) – In a randomized controlled trial, the anti-CA-125 vaccine abagovomab did not prolong survival in patients with ovarian cancer in first remission — despite…
NEW YORK (Reuters Health) – Even without conventional conditioning and cytoxic chemotherapy, an allogeneic hematopoietic cell transplant (HCT) can have a substantial benefit in patients with advanced hematologic…
NEW YORK (Reuters Health) – Intraperitoneal chemotherapy may significantly improve long-term survival in ovarian cancer patients, a new study found. Data from 876 patients followed for a median…
Herbert Lepor, MD, and Danil V. Makarov, MD, MHS, discuss the case of a 58 year-old African American male with lower urinary tract symptoms in Part 1 of…
NEW YORK (Reuters Health) – Anticoagulant use may be a predictor of overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel, retrospective data suggest. The…
